SUNNYVALE, Calif., Nov. 10, 2020 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that innovations in
hardware and software solutions and clinical data presented at this
year's ASTRO (American Society for Radiation Oncology) Annual
Meeting continue to support the use of the company's
CyberKnife® and
TomoTherapy® platforms, including the
next-generation Radixact® System, to deliver
(ultra) hypofractionated radiation treatments.
Hypofractionated radiotherapy — a shorter course of radiotherapy
with higher radiation doses per fraction — provides an efficient
and effective treatment option for an increasing number of
indications and may improve patients' clinical and financial
experiences.
New Standard in Radiation Treatment Delivery
With
more than a decade of clinical proof behind
Synchrony® Motion Synchronization and Real-Time
Adaptive Radiotherapy Technology for the CyberKnife System, Accuray
brought this advanced capability to the Radixact System. The
artificial intelligence (AI)-driven Synchrony technology corrects
for tumors that move as a result of bodily processes, including
respiration and digestion, as well as patient movement, without
uncomfortable patient restraints or breath-hold techniques, or
human intervention. It is the only technology to use image guidance
during radiation delivery to automatically adapt and synchronize
radiation treatment in real-time with the movement of the tumor.
Synchrony enables the medical care team to deliver high precision,
(ultra) hypofractionated radiation treatments with confidence —
knowing that treatment delivery will automatically account for
target movement.
No Trade-Off Sub-Millimeter Precision and Accuracy
The CyberKnife S7™ System is the next-generation CyberKnife
platform, a robotic, non-invasive radiation therapy device capable
of treating cancerous and benign tumors throughout the body, as
well as neurological disorders. The system was built from the
ground-up to provide clinicians with the speed they need for
operational efficiency, without sacrificing the precision and
accuracy required for stereotactic radiosurgery (SRS) and
stereotactic body radiation therapy (SBRT). SRS and SBRT are
advanced external beam radiation treatment techniques used to
deliver (ultra) hypofractionated radiation therapy. The CyberKnife
S7 System, with Synchrony and the VOLO™ Optimizer, facilitates the
delivery of accurate, sub-millimeter, (ultra) hypofractionated
treatments to tumors throughout the body, even to targets that
move, in as little as 15 minutes.
Hypofractionated Treatments — a Proven
Modality
Hypofractionated treatment regimens may expand
medical care team options for achieving outstanding outcomes for a
range of tumors. New data presented at ASTRO includes:
- Prostate Cancer
-
- CyberKnife customers pioneered prostate SBRT. Two studies
confirmed the durability of the clinical response after 4- or
5-fraction CyberKnife SBRT in 640 early-stage prostate cancer
patients followed for at least 10 years1,2.
- Breast Cancer
-
- Multiple studies reinforce the benefits of treating early stage
breast cancer with TomoTherapy or CyberKnife for partial breast
irradiation (PBI).
- Three hundred and thirty-eight patients treated in 10 fractions
delivered with the TomoTherapy System and followed for 72 months
showed excellent long-term results with good to excellent cosmetic
outcomes, reinforcing the role of the system in the treatment of
early stage breast cancer3.
- Two studies evaluating 5-fraction CyberKnife PBI and following
patients for 36 months and 80 months, respectively, confirmed that
treatment was well-tolerated and efficacious4,5.
Moreover, for the first time at ASTRO, the preliminary results of a
1-fraction treatment delivered with the system were reported. The
results for 19 patients are promising in terms of feasibility,
cosmesis and early outcomes, potentially expanding the treatment
options clinicians offer their patients6.
ClearRT™* Helical kVCT Imaging for the Radixact®
System: Unveiled at ASTRO
The most recent innovation for the
Radixact System, ClearRT Helical kVCT Imaging, is intended to
quickly and cost-effectively produce clear, high-fidelity kVCT
images that enhance soft-tissue visualization to improve cancer
patients' care. With the introduction of ClearRT for the Radixact
System, Accuray is delivering on the full promise of the system's
unique helical architecture. The Radixact System is the only
radiation therapy device with helical imaging, helical delivery,
and intrafraction motion synchronization functionality using
Synchrony®, providing expanded versatility and increased
precision to treat the widest range of cases - from simple to the
most complex - with the longest continuous imaging and treatment
fields in the industry, up to 135 cm.
Learn more about ClearRT for the Radixact System here.
*ClearRT™ Helical kVCT Imaging for the Radixact Treatment
Delivery System is 510(k) pending and is not available for sale in
any market.
"We are pleased to have had the opportunity to present our
latest innovations during this important meeting. Our radiation
delivery systems and software solutions provide medical care teams
with cutting-edge options for expanding the range of patients who
may benefit from treatment. We continually invest in transforming
what radiation therapy can do, with the goal of providing
clinicians with more efficient and effective options that can
handle even the most challenging cases, to get patients back to
living their lives, faster," said Suzanne
Winter, chief commercial officer and senior vice president,
R&D at Accuray.
About Accuray
Accuracy is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions to deliver radiation treatments
for even the most complex cases—while making commonly treatable
cases even easier—to meet the full spectrum of patient needs. We
are dedicated to continuous innovation in radiation therapy for
oncology, neuro-radiosurgery, and beyond, as we partner with
clinicians and administrators, empowering them to help patients get
back to their lives, faster. Accuray is headquartered in
Sunnyvale, California, with
facilities worldwide. To learn more, visit www.accuray.com or
follow us on Facebook, LinkedIn, Twitter, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to new products and
innovations, clinical applications, clinical results, patient
experiences and patient outcomes. These forward-looking statements
involve risks and uncertainties. If any of these risks or
uncertainties materialize, or if any of the company's assumptions
prove incorrect, actual results could differ materially from the
results expressed or implied by these forward-looking statements.
These risks and uncertainties include, but are not limited to, the
effect of the COVID-19 pandemic on the operations of the company
and those of its customers and suppliers, the company's ability to
achieve widespread market acceptance of its products; the company's
ability to develop new products or improve existing products to
meet customers' needs; the company's ability to anticipate or keep
pace with changes in the marketplace and the direction of
technological innovation and customer demands and such other risks
identified under the heading "Risk Factors" in the company's
quarterly report on Form 10-Q, filed with the Securities and
Exchange Commission (the "SEC") on November
4, 2020, and as updated periodically with the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Accuray Media Contact
Beth Kaplan
+1 (408) 789-4426
bkaplan@accuray.com
1 D.B. Fuller, R.C. Chen et al. "10 Year
Prostate Stereotactic Body Radiotherapy Outcomes: Relapse-free
Survival, PSA Kinetics and Toxicity from a Pooled Analysis of Two
Multi-institutional Trials." ASTRO 2020 Poster Q&A Session.
International Journal of Radiation Oncology*Biology*Physics Volume
108, Issue 3, Supplement, 1 November
2020, Pages e857-e858.
2 A.J. Katz, J. Kang. "Efficacy and Toxicity of
Stereotactic Body Radiation Therapy for Localized Prostate Cancer:
A Twelve-Year Study." ASTRO 2020 Poster Q&A Session.
International Journal of Radiation Oncology*Biology*Physics Volume
108, Issue 3, Supplement, 1 November
2020, Pages e870-e871.
3 U. de Paula, A.D. Andrulli et al. "Long-Term
Outcomes of Once Daily Accelerated Partial Breast Irradiation with
Tomotherapy: Phase II Trial Results on 338 Women Treated at a
Single Institution." ASTRO 2020 Poster Q&A Session.
International Journal of Radiation Oncology*Biology*Physics Volume
108, Issue 3, Supplement, 1 November
2020, Page e16.
4 H.E. Morgan, D.N. Kim et al. "Three-Year Cosmetic
Outcomes of a Phase I Dose Escalation Trial of 5-Fraction
Stereotactic Partial Breast Irradiation for Early Stage Breast
Cancer." ASTRO 2020 Poster Q&A Session. International Journal
of Radiation Oncology*Biology*Physics Volume 108, Issue 3,
Supplement, 1 November 2020, Pages
e15-e16.
5 J.A. Haas, M.R. Witten et al. "Stereotactic Body
Radiation Therapy for Early-Stage Breast Cancer Using a Robotic
Linear Accelerator-Longer Term Results from a Multi-Institutional
Trial." ASTRO 2020 Poster Q&A Session. International Journal of
Radiation Oncology*Biology*Physics Volume 108, Issue 3, Supplement,
1 November 2020, Page e19.
6 A.S. Rahimi, D.N. Kim et al. "Multi-Institutional
Trial of Phase I Dose Escalation Using Single Fraction Stereotactic
Partial Breast Irradiation (S-PBI) for Early Stage Breast Cancer."
ASTRO 2020 Poster Q&A Session. International Journal of
Radiation Oncology*Biology*Physics Volume 108, Issue 3, Supplement,
1 November 2020, Pages e19-e20.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/accuray-showcases-radiation-therapy-innovations-designed-to-enable-better-outcomes-with-less-damage-less-time-and-less-cost-at-astro-2020-301169232.html
SOURCE Accuray Incorporated